Navigation Links
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
Date:8/5/2009

n and less risk of hypercalcemia. In addition, BA058 in a prefilled cartridge presentation for self-injection has demonstrated long-term stability at room temperature without loss of functionality or impairment of safety and tolerability, an important convenience advantage for patients that would eliminate the refrigeration requirement of daily-injected Forteo(R). Sales of PTH analogs are projected to surpass bisphosphonate sales and reach $2.3 billion by 2018, driven by robust efficacy data in reducing fractures.

About Osteoporosis

Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. In the U.S. alone, more than 44 million men and women have osteoporosis or low bone-mineral density. A 50-year-old woman in the U.S. has a 40 percent lifetime risk of osteoporotic fracture. Twenty percent of hip-fracture patients enter long-term care, and half of this group never returns to living independently.

About Radius (www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

    Contact: Nick Harvey
    Chief Financial Officer
    (617) 551-4704


'/>"/>
SOURCE Radius
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
2. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
3. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
4. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
10. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Mass. , and DURHAM, N.C. ... , Inc. today announced its acquisition of assets related ... (NYSE: PFE ) that had previously been obtained ... XRPro Sciences also acquired all of Pfizer,s rights to ... the Icagen brand and will provide comprehensive services for ...
(Date:7/2/2015)... June 25, 2015 ... announced the addition of the "2015 ... Global Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in Clinical Chemistry and Immunodiagnostics: ... a new seven-country strategic analysis of major ...
(Date:7/2/2015)... 2. Juli 2015 BGI gab heute ... Hongkong vom American College of Pathologists (CAP) ... das erste klinische Next-Generation-Sequencing Labor, das in ... erhält und somit die höchsten Standards an ... US FDA - 21 CFR Part 11 ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... year recurrence data from the Collagenase Optimal Reduction ... (CORDLESS) for XIAFLEX ® (collagenase clostridium histolyticum) ... with a palpable cord. This five year observational ...
... GLOW2 Study Shows NVA237 Provides Superior24-hour Bronchodilation to Placebo ... at 12 Weeks NVA237 Shown to be ... Phase III data Support First Regulatory Submission by ...   Sosei Group Corporation ("Sosei"; TSE ...
Cached Medicine Technology:Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 2Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 3Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 4Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 5Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 6Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 7Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 8Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 9Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD 2Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD 3Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD 4
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium frozen ... companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ... her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on June ... (D-R.I.), this Act seeks to decrease drug overdose – especially of heroin and ...
(Date:7/2/2015)... ... 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry was fully ... to write his first poem, and three years later he was publishing an entire book ... sharing with the world. "I have always believed that the best way to lift yourself ...
(Date:7/2/2015)... GA (PRWEB) , ... July 02, 2015 , ... Global ... newest innovation in compression socks designed for men. , For style that’s quick ... into their daily routine. This is great news for men everywhere because a simple ...
(Date:7/2/2015)... PLAINSBORO, N.J. (PRWEB) , ... July 02, 2015 ... ... ACO and Emerging Healthcare Delivery Coalition met for the late June Web-based ... moves forward with new reimbursement schemes and managing high-risk patients through coordinated care. ...
Breaking Medicine News(10 mins):Health News:sweetfrog Opens First Location in Mississippi 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4
... is Light at the end of the tunnel for HRT ... allowed HRT for treatment of symptoms of menopause, vouching its ... has said that, this would be a reprieve for women ... reported in 2002, which suggested that HRT could increase the ...
... of the pan into the fire itself, the burning problem, ... directives to disclose levels of trans fats in packaged foods, ... trans fat in french fries.// The tests have put French ... more ( 8 grammes as against earlier 6 grams level)trans ...
... of the much dreaded bird flu has been reported from ... The situation is being closely // monitored and is believed ... Agricultural department. ,More than 15, 000 chickens in ... flu virus had died. In response to the above situation, ...
... is launching a nationwide outreach program to improve the ... a follow-up to the Antihypertensive and Lipid-Lowering Treatment to ... in collaboration with the National High Blood Pressure Education ... study had compared the effectiveness of four classes of ...
... of people who suffer from the Ischemic Heart Disease (IHD) ... from // person to person, depending upon whether it ... heart is affected by this medical condition, and where Western ... ,When patients seek medical care for chest pain, ...
... Kenya by the World Bank for HIV/AIDS education and banking ... has been delayed due to some allegations pertaining to corruption ... the Kenyan government, the SAPA/Mail & Guardian reports (SAPA/Mail & ... Health in February 2005 it had failed to distribute $54 ...
Cached Medicine News:Health News:The Decks Cleared For HRT - Safe for Menopause Symptoms 2Health News:Diuretics More Effective In Controlling High Blood Pressure 2
Inquire...
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: